{
  "id": 6256014,
  "title": "Sandoz Issues Mid-term Outlook For 2025-2030; Unveils Bio100 Ambition",
  "url": "https://urgent.news/2026/09/08/sandoz-issues-mid-term-outlook-for-2025-2030-unveils-bio100-ambition",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T05:54:57.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/sandoz-issues-mid-term-outlook-2025-2030-unveils-bio100-ambition"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Sandoz (SDZ.SW) reaffirmed its prevailing mid-term outlook to 2028. The company introduced a new mid-term outlook for 2025 to 2030, targeting mid-to-high single-digit percentage growth in average annual net sales at constant currencies and a core EBITDA margin of 25-2",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}